Exelixis
EXEL
#1826
Rank
$11.69 B
Marketcap
$43.63
Share price
-1.20%
Change (1 day)
18.40%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): $2.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $2.38. In 2023 the company made an earnings per share (EPS) of $0.65 an increase over its 2022 EPS that were of $0.57.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)$2.38
2023$0.6514.61%
2022$0.57-22.97%
2021$0.74100%
2020$0.37-65.09%
2019$1.06-53.91%
2018$2.30333.96%
2017$0.53-260.61%
2016-$0.33-58.75%
2015-$0.80-42.45%
2014-$1.395.3%
2013-$1.32

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
$11.14 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
$1.36-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
$14.33 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
$2.07-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
$7.31 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
$2.97 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
$3.77 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-$3.67-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-$0.84-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA